Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

MS drug TYSABRI to be highlighted at 62nd AAN Annual Meeting

Biogen Idec and Elan Corporation, plc today announced 15 company-sponsored platform and poster presentations at the American Academy of Neurology's (AAN) 62nd Annual Meeting in Toronto, April 10 - 17, 2010. The AAN Annual Meeting is the world's largest gathering of neurologists.

13 Apr 2010

MS Longest Day of Golf event to raise funds for MS research

More than 40 of Michigan's best golf courses are donating greens fees on select dates in May, allowing golfers to play for free while raising funds for multiple sclerosis research, programs and services. 2010 marks the 20th anniversary of the National MS Society Michigan Chapter's "MS Longest Day of Golf" event, which takes place in both May and September.

13 Apr 2010

Uninsured migraine sufferers likely to get inadequate treatment: Neurology

People with no health insurance are less likely than the privately insured to receive proper treatment for their migraines, according to a study published in the April 13, 2010, print issue of Neurology, the medical journal of the American Academy of Neurology.

13 Apr 2010

New patient education video and guidebook for MS patients

Silver screen star Teri Garr is the host of the American Academy of Neurology Foundation's newest patient education video and guidebook, Living Well: A Guide to Managing Multiple Sclerosis for Patients and Families.

12 Apr 2010

AED Vimpat to be the subject of numerous studies and analyses at AAN meeting

The antiepileptic drug Vimpat- (lacosamide) (C-V) will be the subject of numerous studies and analyses-both UCB-sponsored and independent-at the 62nd annual American Academy of Neurology meeting, taking place at the Metro Toronto Convention Centre in Toronto from April 10-17.

9 Apr 2010

Tβ4 therapy for ocular disorders closer to reality

RegeneRx Biopharmaceuticals, Inc. announced today that Tβ4, a synthetic version of a naturally occurring peptide that is the basis for the company's product candidates, will be the subject of three poster presentations at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) to be held in Fort Lauderdale, Florida from May 2-6, 2010.

9 Apr 2010

"Nanovaccine" reverses diabetes

A new study, published online April 8 by Cell Press in the journal Immunity, describes a unique therapeutic "nanovaccine" that successfully reverses diabetes in a mouse model of the disease. In addition to providing new insight into diabetes, the research also reveals an aspect of the pathogenesis of the autoimmune response that may provide a therapeutic strategy for multiple autoimmune disorders.

9 Apr 2010

Nanotechnology-based vaccine cures mice with type 1 diabetes

Using a sophisticated nanotechnology-based "vaccine," researchers were able to successfully cure mice with type 1 diabetes and slow the onset of the disease in mice at risk for the disease. The study, co-funded by the Juvenile Diabetes Research Foundation, provides new and important insights into understanding how to stop the immune attack that causes type 1 diabetes, and could even have implications for other autoimmune diseases.

9 Apr 2010

Smoking may increase risk of MS in people who have established risk factors for MS

A new study shows that smoking may increase the risk of multiple sclerosis in people who also have specific established risk factors for MS. The research is found in the April 7, 2010, online issue of Neurology, the medical journal of the American Academy of Neurology.

8 Apr 2010

Role of beta defensins in development of chronic inflammatory response in the brain

Researchers at the Case Western Reserve University School of Dental Medicine and School of Medicine will look for evidence within the brain for human beta defensin peptide function-proteins important to the peripheral body's natural defense system against infection from the outside environment.

8 Apr 2010

New studies supporting Teva Pharmaceutical Industries' CNS portfolio to be presented at AAN 2010

Teva Pharmaceutical Industries Ltd. today announced that several new studies supporting the company's innovative central nervous system portfolio will be presented at the 62nd American Academy of Neurology Annual Meeting in Toronto, April 10-17, 2010.

8 Apr 2010

Women living in northeastern U.S. more likely to develop RA: Study

Women living in the northeastern United States are more likely to develop rheumatoid arthritis, suggesting a link between the autoimmune disease and vitamin D deficiency, says a new study led by a Boston University School of Public Health researcher.

8 Apr 2010

Study demonstrates potential ability of Chronix serum DNA assays in diagnosis of breast cancer

Chronix Biomedical today announced publication of a study that supports the utility of its serum DNA blood tests to predict clinical status and monitor disease activity and response to treatment in multiple sclerosis (MS). Chronix Biomedical uses proprietary technology to identify disease-specific genetic fingerprints based on the circulating DNA that is released into the bloodstream by damaged and dying cells.

7 Apr 2010

Opexa Therapeutics to present data from Phase 2b TERMS clinical trial for Tovaxin at 62nd AAN meeting

Opexa Therapeutics, Inc., a company developing a novel T-cell therapy for multiple sclerosis (MS), announced today that the Company has been selected to present key efficacy data at the upcoming American Academy of Neurology (AAN) 62nd Annual Meeting to be held in Toronto, Canada.

7 Apr 2010

AbleNet adds Madentec's entire line of assistive technology solutions to product portfolio

AbleNet, Inc. announces the agreement with Madentec Limited of Edmonton, Alberta, Canada for the exclusive global rights to manufacture and sell their entire line of assistive technology solutions. This adds a broad portfolio of proven devices to the AbleNet computer access products. Madentec will continue to own the products and provide engineering development support, which has been their core strength.

7 Apr 2010

New study shows utility of Chronix Biomedical's serum DNA tests in MS

Chronix Biomedical today announced publication of a study that supports the utility of its serum DNA blood tests to predict clinical status and monitor disease activity and response to treatment in multiple sclerosis. Chronix Biomedical uses proprietary technology to identify disease-specific genetic fingerprints based on the circulating DNA that is released into the bloodstream by damaged and dying cells.

6 Apr 2010

Dalfampridine drug for multiple sclerosis now available in the U.S.

A drug whose clinical benefit in treating multiple sclerosis was discovered at Rush University Medical Center was approved by the Food and Drug Administration on January 22 and is now available in the U.S.

6 Apr 2010

Free online training program for saving individuals with disabilities during fire emergencies

United Spinal Association has developed a free online training program designed to save the lives of individuals with disabilities and mobility impairments during fire emergencies.

5 Apr 2010

Disability Leadership and Policy Summit to be hosted in Philadelphia, Pennsylvania

United Spinal Association will host its inaugural Disability Leadership and Policy Summit on April 15th in Philadelphia, commemorating the 20th Anniversary of the Americans with Disabilities Act, which was signed into law on July 26, 1990 and prohibits discrimination based on disability. The law was amended in 2008 to offer more protection to disabled workers.

5 Apr 2010

Opexa Therapeutics to discuss on personalized medicine for treatment of MS

Opexa Therapeutics, Inc., a company developing a novel T-cell therapy for multiple sclerosis, announced today that the company will participate in a panel discussion on Personalized Medicine for the Treatment of Multiple Sclerosis on April 7, 2010.

5 Apr 2010

Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

MS drug TYSABRI to be highlighted at 62nd AAN Annual Meeting

MS Longest Day of Golf event to raise funds for MS research

Uninsured migraine sufferers likely to get inadequate treatment: Neurology

New patient education video and guidebook for MS patients

AED Vimpat to be the subject of numerous studies and analyses at AAN meeting

Tβ4 therapy for ocular disorders closer to reality

"Nanovaccine" reverses diabetes

Nanotechnology-based vaccine cures mice with type 1 diabetes

Smoking may increase risk of MS in people who have established risk factors for MS

Role of beta defensins in development of chronic inflammatory response in the brain

New studies supporting Teva Pharmaceutical Industries' CNS portfolio to be presented at AAN 2010

Women living in northeastern U.S. more likely to develop RA: Study

Study demonstrates potential ability of Chronix serum DNA assays in diagnosis of breast cancer

Opexa Therapeutics to present data from Phase 2b TERMS clinical trial for Tovaxin at 62nd AAN meeting

AbleNet adds Madentec's entire line of assistive technology solutions to product portfolio

New study shows utility of Chronix Biomedical's serum DNA tests in MS

Dalfampridine drug for multiple sclerosis now available in the U.S.

Free online training program for saving individuals with disabilities during fire emergencies

Disability Leadership and Policy Summit to be hosted in Philadelphia, Pennsylvania

Opexa Therapeutics to discuss on personalized medicine for treatment of MS

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in